Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2018

Conditions
Enterocolitis Clostridium Difficile Recurrent
Interventions
BIOLOGICAL

RBX2660 (microbiota suspension)

A suspension of intestinal microbes

OTHER

Placebo

A suspension of saline and cryoprotectant

Trial Locations (21)

10065

New York-Presbyterian Hospital/Weill Cornell Medical College, New York

11355

New York Hospital Queens, Flushing

14618

Gastroenterology Group of Rochester, Rochester

19104

Hospital of the University of Pennsylvania, Philadelphia

20815

Chevy Chase Clinical Research, Chevy Chase

32256

Borland-Groover Clinic, Jacksonville

44106

Louis Stokes Cleveland VA Medical Center, Cleveland

45801

Regional Infectious Diseases and Infusion Center, Lima

46260

Infectious Diseases of Indiana, Indianapolis

48202

Henry Ford Health System, Detroit

55101

Regions Hospital, Saint Paul

55905

Mayo Clinic Minnesota, Rochester

58122

Sanford Health, Fargo

60153

Loyola University Chicago, Chicago

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

80045

University of Colorado, Aurora

83404

Grand Teton Research Group, Idaho Falls

85054

Mayo Clinic Arizona, Phoenix

V5Z 1M9

University of British Columbia, Vancouver

L8N 4A6

St. Joseph's Hospital, Hamilton

All Listed Sponsors
lead

Rebiotix Inc.

INDUSTRY

NCT02299570 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection | Biotech Hunter | Biotech Hunter